Design Therapeutics, Inc.

Healthcare

NASDAQ:DSGN · NASDAQ Global Select

Market Cap $665.79M Beta 1.66 P/E (TTM) -9.7

$10.97 +4.18%

+$0.44 today

52W Low $3.33High $17.25

Vol 0.46M · Avg 0.73M

EPS (TTM)-$1.13

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+185.68%

Period High

$15.79

Period Low

$3.37

Latest

$10.97

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

$814.99M

Annexon, Inc.

NASDAQ:ANNX

$563.29M

Aura Biosciences, Inc.

NASDAQ:AURA

$411.52M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

$304.44M

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

$300.28M

I-Mab

IMAB

$235.66M

Altimmune, Inc.

NASDAQ:ALT

$230.35M

Galectin Therapeutics Inc.

NASDAQ:GALT

$175.84M

Korro Bio, Inc.

NASDAQ:KRRO

$115.56M

enGene Holdings Inc.

NASDAQ:ENGN

$82.94M

What is the latest DSGN filing?

The latest filing shown is 4 dated Jun 11, 2026.

How many recent filings does DSGN have?

Intrinsic Alpha currently shows 20 recent filings for DSGN.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.